All In Biotech

Drug Trial Radar · NCT06520345

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Jul 26, 2024

Primary completion

Dec 2027

Study completion Dec 2030

Sponsor

Sponsor type
Industry
First posted
Jul 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • 177Lu-TLX591Drug

    Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart

  • EnzalutamideDrug

    Enzalutamide (starting dose 160 mg daily)

  • AbirateroneDrug

    Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (up to 10 mg per day for the standard formulation)

  • DocetaxelDrug

    Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone 5mg twice a day (or equivalent) for up to 10 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression-free SurvivalTime frame: 337days

Locations

33 sites in 6 countries. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Centre

    Orange, California · Active not recruiting

  • Biogenix Molecular LLC

    Miami, Florida · Active not recruiting

  • United Theranostics

    Glen Burnie, Maryland · Active not recruiting

  • XCancer Omaha

    Omaha, Nebraska · Active not recruiting

  • Columbia University Herbert Irving Comphrensive Cancer Center

    New York, New York · Recruiting

  • University Hospital

    Cleveland, Ohio · Active not recruiting

  • OHSU Knight Cancer Center

    Portland, Oregon · Active not recruiting

  • Intermountain Health

    Murray, Utah · Active not recruiting

  • Intermountain Health

    Salt Lake City, Utah · Active not recruiting

  • Mater Health Services Pty Ltd

    Brisbane, Australia · Not yet recruiting

  • GenesisCare Maitland

    East Maitland, Australia · Recruiting

  • Austin Health

    Heidelberg, Australia · Recruiting

  • GensisCare Cabrini

    Malvern, Australia · Recruiting

  • GenesisCare North Adelaide

    North Adelaide, Australia · Recruiting

  • Royal North Shore Hospital

    Saint Leonards, Australia · Recruiting

  • GenesisCare Tugun

    Tugun, Australia · Recruiting

  • Westmead Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Nepean Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Wollongong Hospital

    Wollongong, New South Wales, Australia · Recruiting

  • Australian Prostate Centre

    Melbourne, Victoria, Australia · Recruiting

  • GenesisCare Murdoch

    Perth, Western Australia, Australia · Recruiting

  • INITIO Medical Group

    Burnaby, Canada · Recruiting

  • Sunnybrook Research Institute

    Toronto, Canada · Recruiting

  • New Zealand Clinical Research - Christchurch

    Christchurch, New Zealand · Recruiting

  • Auckland City Hospital

    Grafton, Auckland, New Zealand · Recruiting

  • Ankara Bilkent City Hospital

    Ankara, Turkey (Türkiye) · Not yet recruiting

  • Ankara University Cebeci Hospital

    Ankara, Turkey (Türkiye) · Recruiting

  • Hacettepe University Medical Faculty

    Ankara, Turkey (Türkiye) · Recruiting

  • Maslak Acibadem Hospital

    Istanbul, Turkey (Türkiye) · Recruiting

  • Charing Cross Hospital

    London, United Kingdom · Recruiting

  • Royal Free Hospital

    London, United Kingdom · Not yet recruiting

  • University College London Hospitals

    London, United Kingdom · Recruiting

  • Genesiscare Windsor

    Windsor, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.